Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.54 is 37% above its 5-year average of -0.86, near the high end of its 5-year range (-1.06–-0.54).
25.24% above its 12-month average of -0.72.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:25:14.984Z. Historical observations retain their original dates. Historical series through 2020-05-04.
EARNINGS PER SHARE (EPS)
-0.54
EARNINGS PER SHARE (EPS) AVG TTM
-0.72
EARNINGS PER SHARE (EPS) AVG 3Y
-0.78
EARNINGS PER SHARE (EPS) AVG 5Y
-0.86
EARNINGS PER SHARE (EPS) AVG 10Y
-0.51
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.24%
CURRENT VS 3Y AVG
+30.86%
CURRENT VS 5Y AVG
+37.19%
CURRENT VS 10Y AVG
-6.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AC Immune S.A.
Market Cap
$275.81M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.72
3Y Avg
-0.78
5Y Avg
-0.86
Market Cap
$276.26M
Earnings Per Share (EPS)
-1.39
TTM Avg
-0.76
3Y Avg
-0.82
5Y Avg
-19.50
Market Cap
$283.06M
Earnings Per Share (EPS)
-1.21
TTM Avg
-0.67
3Y Avg
-1.32
5Y Avg
-1.70
Market Cap
$283.24M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
Market Cap
$267.99M
Earnings Per Share (EPS)
-1.04
TTM Avg
-0.86
3Y Avg
-1.57
5Y Avg
-1.50
Market Cap
$284.24M
Earnings Per Share (EPS)
-6.97
TTM Avg
-33.27
3Y Avg
-41.62
5Y Avg
-70.95
Market Cap
$264.10M
Earnings Per Share (EPS)
-3.74
TTM Avg
-2.75
3Y Avg
-2.51
5Y Avg
-2.60
Market Cap
$264.07M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
Market Cap
$264.05M
Earnings Per Share (EPS)
-0.27
TTM Avg
-2.29
3Y Avg
-2.81
5Y Avg
-2.11
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AC Immune S.A. (ACIU) | $275.81M | -0.54 | -0.72 | -0.78 | -0.86 |
| Aurora Cannabis Inc. (ACB)vs › | $276.26M | -1.39 | -0.76 | -0.82 | -19.50 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.06M | -1.21 | -0.67 | -1.32 | -1.70 |
| Fate Therapeutics, Inc. (FATE)vs › | $283.24M | -1.05 | -1.40 | -1.83 | -1.95 |
| Century Therapeutics, Inc. (IPSC)vs › | $267.99M | -1.04 | -0.86 | -1.57 | -1.50 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $284.24M | -6.97 | -33.27 | -41.62 | -70.95 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.10M | -3.74 | -2.75 | -2.51 | -2.60 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.07M | -0.48 | -0.82 | -2.37 | -2.68 |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | -0.27 | -2.29 | -2.81 | -2.11 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $288.39M | N/A | -2880.36 | -1920.24 | -1440.18 |
Trailing EPS (TTM)
$-0.54
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.88 |
| 2024-12-31 | -0.56 |
| 2023-12-31 | -0.76 |
| 2022-12-31 | -0.92 |
| 2021-12-31 | -1.06 |
| 2020-12-31 | -0.97 |
| 2019-12-31 | 0.66 |
| 2018-12-31 | -0.83 |
| 2017-12-31 | -0.47 |
| 2016-12-31 | -0.14 |
| 2015-12-31 | 0.37 |
| 2014-12-31 | 0.19 |
| 2013-12-31 | -0.31 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T13:25:14.984Z. Historical observations retain their original dates. Historical series through 2020-05-04.
